Chitosan-based liposomal thermogels for the controlled delivery of pingyangmycin: design, optimization andin vitroandin vivostudies

Ling Zhang, Fen Chen, Jiatong Zheng, Hongwei Wang, Xingjun Qin, Weisan PanDrug 2018 · DOI

TL;DR

This study developed a novel chitosan-based liposomal thermogel system for the controlled, localized delivery of pingyangmycin (PYM), an anti-tumor antibiotic. The optimized formulation demonstrated sustained PYM release in vitro and in vivo, effectively inhibiting vascular malformation growth in rabbits with reduced side effects compared to conventional PYM delivery methods.

What Problem Does This Paper Address?

Pingyangmycin (PYM) is a clinically used drug for treating vascular malformations (VMs) and certain cancers. However, its current administration as a simple injection leads to rapid diffusion from the injection site. This quick diffusion not only reduces the drug's therapeutic efficacy at the target site but also increases the risk of systemic side effects, particularly pulmonary injury. To overcome these limitations, there's a need for a delivery system that can provide sustained and localized release of PYM at the site of action.

Methods

The researchers employed a multi-pronged approach:

  • Liposome Preparation: PYM was encapsulated within liposomes using an ammonium sulfate gradient technique. This method aims to trap the drug within the lipid bilayer for controlled release.
  • Thermogels Formulation: Chitosan (CS) and glycerol phosphate disodium (GP) were used to create in situ thermogels. These hydrogels are liquid at room temperature but solidify at body temperature, forming a depot at the injection site.
  • Liposomal Thermogel Integration: The PYM-loaded liposomes were then incorporated into the CS/GP thermogel system. This combines the sustained release properties of liposomes with the localized delivery and in situ gelation of thermogels.
  • Optimization using Box-Behnken Design: A statistical design of experiments (Box-Behnken) was used to systematically optimize the formulation parameters, specifically the PYM concentration, CS amount, and GP content. This allowed the researchers to identify the ideal combination for desired release profiles.
  • In Vitro Studies:
    • Drug Release: Cumulative PYM release was measured over 14 days to assess the sustained release capability.
  • Cytotoxicity Assays: Human vascular endothelial cells (EA.hy926) were used to evaluate the anti-proliferative effects of the PYM-loaded liposomal thermogels through cell cycle analysis and apoptosis assays. Morphological changes were also observed.
  • In Vivo Studies:
    • Pharmacokinetics in Rabbits: The blood concentration of PYM over time was measured in rabbits after administration of PYM liposomes, PYM thermogels, and PYM liposomal thermogels to assess systemic absorption and half-life.
  • Chemoembolization in Rabbits: Rabbit ear veins were treated with the formulations, and histological examinations (H&E staining) were performed at various time points to assess the therapeutic effect (e.g., vein thrombosis, inflammation) and local tissue response.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Synergistic Delivery System: Combining liposomes with chitosan/glycerophosphate thermogels creates a powerful dual-action delivery system. Liposomes provide initial encapsulation and sustained release, while the thermogel ensures localized delivery and in situ gelation at body temperature.
  • Statistical Optimization is Crucial: The Box-Behnken design was instrumental in identifying the optimal balance of PYM, CS, and GP concentrations to achieve the desired release profile (low initial release, high sustained release).
  • Thermogels Enhance Localized Drug Action: The in vivo studies clearly showed that the liposomal thermogels significantly prolonged PYM's presence at the injection site compared to liposomes or thermogels alone, leading to better therapeutic outcomes.
  • PYM's Cytotoxicity is Formulation-Dependent: While PYM itself is cytotoxic, the liposomal thermogel formulation demonstrated effective anti-proliferative action on vascular endothelial cells without significant toxicity from the gel components themselves.
  • Therapeutic Mechanism: The in vivo histological findings suggest that the liposomal thermogels induce vein embolism, followed by controlled PYM release, leading to hyperplasia of endothelial cells and eventual venous occlusion – a multi-faceted approach to treating VMs.

Key Results

  • Optimized Formulation: The optimal formulation consisted of 4.68 mg/mL PYM, 2.05% (w/v) CS, and 11.57% (w/v) GP.
  • In Vitro Release: The optimized formulation showed controlled PYM release for up to 14 days, with 17.24% released in 1 day and 80.77% released in 9 days. This is a significant improvement over rapid diffusion.
  • In Vitro Efficacy: PYM liposomal thermogels effectively inhibited the proliferation of EA.hy926 cells, inducing apoptosis and necrosis.
  • In Vivo Pharmacokinetics: The half-life (t1/2) of PYM liposomal thermogels was significantly longer (6.54 ± 1.75 h) compared to PYM thermogels (2.69 ± 0.23 h) and PYM liposomes (0.70 ± 0.11 h). The Mean Residence Time (MRT) was also substantially prolonged.
  • In Vivo Therapeutic Effect: Histological examination of rabbit ear veins showed that PYM liposomal thermogels led to obvious vein thrombosis and inflammatory reactions after 21 days, indicating effective embolization and therapeutic action.

Limitations and Future Work

  • Limited In Vivo Data Points: While histological analysis was performed at 2, 7, 14, and 21 days, a more comprehensive time course for in vivo drug concentration and therapeutic effect could provide further insights.
  • Specific Cancer Types: The study focused on vascular malformations. Future work could explore the efficacy of this system for other types of tumors where PYM is indicated.
  • Long-Term Safety: While the blank thermogels showed good biocompatibility, longer-term safety studies of the PYM liposomal thermogels in animal models would be beneficial.
  • Human Trials: The ultimate validation would involve clinical trials in human patients to confirm efficacy and safety for VM treatment.

Summary updated

Abstract

Pingyangmycin (PYM) has been applied clinically for many years to treat vascular malformations (VM) in China. The major limitation of PYM injections is quick diffusion from the injection site, which increases side effects, especially the possibility of pulmonary injury. In this paper, chitosan/glycerophosphate disodium (CS/GP) thermogels containing liposomes for sustained and localized PYM delivery were prepared and optimized by a three-level three-factorial Box-Behnken experimental design to evaluate the effects of different variables (the PYM concentration, CS amount and GP content), on the selected responses (cumulative percentage PYM released in 1 day, 9 days and the rate constant k). The results revealed that the optimized PYM liposomal thermogels had a controlled PYM release for 14 days in vitro, which confirmed the validity of optimization. In vitro morphological observation, cell cycle and apoptosis analysis showed an effective anti-proliferation action of PYM liposomal thermogels on human vascular endothelial cells (EA.hy926). In vivo pharmacokinetics research in rabbits displayed that compared with PYM liposomes and PYM thermogels, PYM liposomal thermogels had a better controlled delivery of PYM. Histological examination of rabbit ear veins showed that after local application with PYM lipsomal thermogels for 21 days, obvious vein thrombosis and inflammatory reaction could be observed. The above results indicated that PYM-loaded lipsomal CS/GP thermogels might have a good prospect for the treatment of VM.
BibTeX
@inproceedings{zhang2018chitosan,
  author = {Ling Zhang and Fen Chen and Jiatong Zheng and Hongwei Wang and Xingjun Qin and Weisan Pan},
  title = {{Chitosan-based liposomal thermogels for the controlled delivery of pingyangmycin: design, optimization and<i>in vitro</i>and<i>in vivo</i>studies}},
  booktitle = {Drug},
  year = {2018},
  doi = {10.1080/10717544.2018.1444684},
}
Figure